UK’s CRT Pioneer Fund to invest in new blood cancer drugs

UK’s Cancer Research Technology (CRT) Pioneer Fund has announced an investment to develop a new class of drugs for blood cancer, which will target a protein called B-cell lymphoma 6 (BCL6).Scientists at the Institute of Cancer Research, London, will use the fund to support their design of the drugs, to treat patients with Diffuse Large BCL6, a sub-type of non-hodgkin lymphoma.CRT, the commercialisation arm of Cancer Research UK, and the European Investment Fund (EIF) launched the fund in 2012 to bridge the funding gap between cancer drug discovery and early drug development.